FDA Expands ASCENIV Pediatric Use
Label change follows completion of required pediatric evaluation and updates prior age restrictions for treatment eligibility.
By
Kathryn Wighton
May 4, 2026
Clinical Scorecard: FDA Expands ASCENIV Pediatric Use
At a Glance
Category Detail
Condition Primary Humoral Immunodeficiency Key Mechanisms Plasma-derived, polyclonal intravenous immune globulin Target Population Pediatric patients aged 2 years and older Care Setting Outpatient and inpatient settings
Key Highlights
ASCENIV now approved for pediatric patients aged 2 years and older Previously indicated for patients aged 12 years and older Approval based on supplemental biologics license application Produced using patented plasma donor screening and pooling methods Carries warnings for thrombosis, renal dysfunction, and acute renal failure Guideline-Based Recommendations
Diagnosis
Assess for primary humoral immunodeficiency in pediatric patients Management
Administer ASCENIV as per dosing guidelines for pediatric patients Monitoring & Follow-up
Monitor renal function in patients at risk of renal dysfunction Risks
Be aware of potential adverse events including thrombosis and hypersensitivity reactions Patient & Prescribing Data
Pediatric patients with primary humoral immunodeficiency
Monitor for common adverse events such as headache and upper respiratory infections
Clinical Best Practices
Ensure thorough patient history to identify risk factors for thrombosis Educate caregivers about potential side effects and when to seek medical attention Implement regular follow-up to assess treatment efficacy and safety Related Resources & Content
